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Biological complexity is a barrier to ful-
ﬁlling the potential of biotechnology.
Large numbers of complex experi-
ments are required to overcome this
barrier.
Performing such complex experiments
requires sophisticated software and
hardware.
New programming languages and soft-
ware tools for this are developing
quickly.
Low-cost automation and sensors pro-
mise to unlock these techniques for all.
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Building robust manufacturing processes from biological components is a task
that is highly complex and requires sophisticated tools to describe processes,
inputs, and measurements and administrate management of knowledge, data,
and materials. We argue that for bioengineering to fully access biological
potential, it will require application of statistically designed experiments to
derive detailed empirical models of underlying systems. This requires execution
of large-scale structured experimentation for which laboratory automation is
necessary. This requires development of expressive, high-level languages that
allow reusability of protocols, characterization of their reliability, and a change in
focus from implementation details to functional properties. We review recent
developments in these areas and identify what we believe is an exciting trend
that promises to revolutionize biotechnology.
Biology, Context Sensitivity, and Reproducibility
The 21st century will be the century of biotechnology [1,2] – the economic contribution of biotech
is set to grow substantially [3,4] and it has been suggested that biotechnology offers solutions to
a variety of crises faced by humanity such as climate change [5], the supply of food [6], energy via
biofuels [7], and tackling escalating healthcare costs.
However, particularly with regard to the cost of healthcare, a number of authors have argued that
the pharma sector is itself in crisis [8–11]. They warn of a looming danger of signiﬁcantly diminishing
returns on R&D expenditure in the pharmaceutical industry [12], a phenomenon somewhat
facetiously known as ‘Eroom's law’. This ‘law’ is purportedly the inverse of Moore's law (which
describes an exponential increase in integrated circuit transistor density over time) and denotes
an exponential decrease in ROI (return on investment) for investment in pharmaceutical R&D. In
an analysis of the underlying causes, Cooke [11] suggested that, in addition to the economic
factors, there are substantial problems with the fundamental framework of biological research.
Speciﬁcally, following comments made by Lord Winston [13] and echoing the rallying cry of
systems biology, it is suggested that the basis of pharmaceutical research is too narrow, linear,
and gene-centric, and fails to properly account for the true complexity of biological systems.
There may be other signs of impending problems: several recent studies have reported low rates
of reproducibility across several areas of science including drug discovery [14], psychology [15],
synthetic biology [16], medicine [17,18], and cancer research [19]. One recent study estimated
that the annual economic cost of irreproducible research in the life sciences is $28 billion [20].214 Trends in Biotechnology, March 2016, Vol. 34, No. 3 http://dx.doi.org/10.1016/j.tibtech.2015.11.006
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Glossary
Categorical factor: a type of factor
in which no relation between the
different levels exists. Examples might
be choice of growth medium,
promoter type, or choice of coding
sequence. (cf. continuous factor.)
Continuous factor: a type of factor
in which there is an intrinsic
quantitative relationship between
different levels. Examples might be
temperatures, lengths of time, or
concentrations of media
components. (cf. categorical factor.)
Critical material attribute (CMA):
in QbD, a key property of a material
input that affects the quality of the
output of the production process.
Critical process parameter (CPP):
in QbD, a key variable affecting the
quality of either the output of a
production process or a critical
quality attribute.
Critical quality attribute (CQA): in
QbD, a key attribute that can be
measured and that correlates with
the quality of the output of the
production process.
Factor: any controlled experimental
variable tested in an experiment.
Usually grouped into two types:
categorical or continuous (qqv).
Interaction: the combined effect of
several factors as distinct from what
would be expected only from the
main effects of those factors.
Interactions are deﬁned to have an
order that quantiﬁes the number of
factors involved. For example, two-
factor interactions quantify the effect
of the level of one factor upon the
change induced by varying the other.
Level: an individual setting of a
particular factor. Most experimental
designs assign the same number of
levels to all factors. Two, three, and
ﬁve levels are the most common
choices.
Main effect: the effect of a single
factor on the response.
OFAT/OVAT: one factor (variable) at
a time. Terms used by DoE initiates
to describe the traditional deﬁnition of
scientiﬁc practice by contrast to the
DoE approach of changing multiple
factors simultaneously.
Principal component analysis
(PCA): one of a large number of
closely related techniques for
multivariate data analysis that apply
matrix decomposition methods to
arrays derived from high-dimensional
data with the aim of ﬁnding lower-
dimensional representations thatAnalyses of the possible causes of these problems and suggested solutions include a need for
improved statistical practice and better management structures [21,22], non-identiﬁability of
research resources [23], basic ﬂaws in experimental practice either deliberate or not [24–26], and
intrinsic variability in key workhorses such as antibodies [27]. A recent article by Ioannidis
highlights a need for openness, quality engineering, and proper statistical control as critical to
achieving reproducible research suitable for development purposes [28].
One recent report of non-misconduct-related article retractions in PubMed found that contami-
nation and errors in analytical procedures, such as sequencing and cloning, were the major
sources of error, with contamination of diminishing and analytical errors of increasing importance
over time [29]. Contamination has further been identiﬁed as a major source of errors in large
sequencing studies [30]. Of particular importance is the ability to deﬁne unambiguously the initial
conditions prevailing when the process was performed [31].
These issues preventing reproducibility can be viewed as problems in the infrastructure of
research in biology on several levels: at the lowest level there is a philosophical and methodological
failure to properly embrace the highly complex and context-sensitive nature of biological systems.
This may be at least partly the consequence of a methodological attachment to an overly strict
interpretation of the OFAT (one factor at a time) (see Glossary) philosophy commonly taught
as fundamental to the scientiﬁc method, but a much greater problem is the sheer difﬁculty of
implementation that comes with the substantially greater experimental complexity that is required.
Compounding this, the languages that are used to describe and exchange protocols and
workﬂows are imprecise, being based almost entirely on natural language, and are only
executable by highly trained expert humans. These means of exchange are poorly suited to
engineering problems of such complexity and scope as are necessary to properly tackle
biological engineering. The reliance on human execution is an unfortunate consequence of this
and traps us in a situation of low-throughput, high-variance experimentation by workers who are
massively overqualiﬁed for much of their day-to-day work. Data collection requires substantial
manual efforts leading to the crucial details of context going unrecorded and contributing to
unexplained variance in processes.
Finally, there is a lack of tools for designing experiments, managing data, and efﬁciently
consolidating the huge amounts of data that are necessary to work in such a complex domain.
Experimental plans are generated principally in terms of the details of execution, leading to a lack
of reusability and an excessive focus on the low-level details.
Automated execution of high-dimensional experimental designs, facilitated by novel program-
ming languages for biological data representation and protocol deﬁnitions powering sophisti-
cated design and analysis tools, promises to help solve many of these problems. We review
these developments in the following sections.
Design of Experiments for High-Dimensional Experimentation
Design of experiments (DoE) is a blanket term for a body of techniques for experimental search
and optimization originally devised at Rothamsted by Fisher and developed by many others
[32–34]. The principal feature of DoE is the use of structured experimentation to simultaneously
investigate the effects of making many changes at once. A key application of these techniques
is the method of response surface optimization, widely applied in optimizing the productivity
and robustness of industrial processes.
The main beneﬁt of this is the ability to detect interactions between experimental factors,
allowing context sensitivity of the effects of experimental changes to be addressed. This is inTrends in Biotechnology, March 2016, Vol. 34, No. 3 215
capture the majority of the observed
variation.
Process analytical technology
(PAT): is a mechanism to design,
analyze, and control pharmaceutical
manufacturing processes through the
measurement of critical process
parameters that affect critical quality
attributes.
Quality by design (QBD): a quality
framework for process development,
deﬁnition, and quality assurance.
Typically this comprises (i) risk
assessment (or failure mode and
effects analysis) to identify potential
causes of failure in the process; (ii)
design space characterization (usually
by DoE) to identify and model critical
effectors of product quality; and (iii)
deﬁning methods to monitor and
control the identiﬁed effectors of
product quality.
Response: an experimental output
of interest, determined by
measurement and usually the subject
of optimization or quality targets.
Response surface methodology
(RSM): an optimization technique as
a result of Box and others combining
hill-climbing procedures with
experimental designs aimed at
modeling responses with second-
order polynomial functions.
Run: a combination of factor settings
with one or more measured
responses, a unit of a designed
experiment.contrast to the more traditional prescription of changing only one factor at a time, which cannot
identify interaction effects. In the face of the very high complexity of bioprocesses, this is a
serious limitation. A particularly attractive feature of this mode of experimentation is very high
efﬁciency in a number of experimental runs: sophisticated designs for exploring very high-
dimensional spaces have been developed, allowing the number of factor effects investigated to
approach or exceed the number of experimental runs [35–38].
Despite these advantages, uptake of methods from DoE in many areas of basic biological
research has been slow, with a few examples scattered across application areas [39–42] and
some useful work recently published on the utility of different designs in some real case studies
[43]. Contrastingly, these techniques are routine in the more industrialized and manufacturing-
oriented sectors of biotechnology [44–47]. The situation is improving, however, with some
interesting recent applications in protein engineering [48], strain engineering [49–51], develop-
ment of whole cell biocatalysis [52], and genetic part characterization [53].
DoE techniques are exceptionally useful in improving the speed and efﬁciency of R&D; however,
arguably their most important application is in the body of practices known variously as quality
by design (QbD) or process analytical technology (PAT). The purpose of QbD is to ensure
that the outputs of production processes are as insensitive as possible to variations in the quality
of inputs or process parameters such as environmental conditions [54]. A related idea is that of
design for manufacture (DfM), which aims to model economic consequences of choices made at
the design stage that will be incurred at the manufacturing stage, attempting to choose designs
that will be cheapest for manufacturing within required quality bounds. Use of these techniques
requires detailed knowledge of interactions between these sources of process sensitivity and
controllable parameters and therefore relies on the use of techniques such as the above that are
able to estimate these interactions.
Developments of QbD approaches relevant to the pharmaceutical industry are reviewed in
[55–58]. A framework for how this may be applied to biosciences research is presented in
Figure 1. The majority of recent applications of QbD in biotechnology research are directed
towards improvement of analytics [59–62].
Of critical importance to the practical realization of QbD/PAT and DfM is the ability to identify
critical quality attributes (CQAs). This creates an emphasis on measurement, requiring
interpretation of highly complex sets of data from related experiments. Typically, these very
high-dimensional datasets contain much correlated information with a relatively small number of
underlying features driving the observed variation. Techniques from machine learning and
multivariate statistics are required to untangle these complex interdependencies and we brieﬂy
summarize these in the following section.
Analysis of High-Dimensional Data
There exist many statistical methods for dealing with high-dimensional legacy data such as
principal component analysis (PCA), partial least squares (PLS) regression, independent
component analysis (ICA), ridge regression, lasso regression, canonical correlation, structural
equation modeling (SEM), etc. Modern machine learning techniques such as neural networks,
decision trees, and support vector machines provide another means to capture complex
nonlinear relationships between a set of observed inputs and observed outputs.
The relationship between these methods and the experimental design techniques and imple-
mentation tools we describe is interesting and potentially extraordinarily rich and practically
useful. All of the methods used above provide alternative means to analyze large datasets with
high apparent dimensionality, usually by deﬁning a lower-dimensional subspace of the inputs,216 Trends in Biotechnology, March 2016, Vol. 34, No. 3
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Figure 1. Challenges and Process of How a Quality by Design (QbD) Framework Could be Applied to
Research in the Biosciences. (A) The train of unit operations involved in a typical biosciences experiment, which may be
undertaken in a research laboratory, in this case expression and characterization of an enzyme. This closely matches the
ﬂow of unit operations that would be involved in the manufacturing of a regulated pharmaceutical and, in principle, similar
quality approaches used to ensure pharmaceutical quality could be applied to less-regulated ‘grass-roots’ research in the
biosciences. (B) For one of these unit operations (fermentation) the variables that could affect product quality are listed and
categorized into input material attributes, process parameters, and quality attributes of the process output. (C) High-
dimensional experimentation based on Design of Experiments (DoE) is applied to identify which of the parameters are critical
to overall product quality. (D) List of critical material attributes (CMAs), critical process parameters (CPPs), and
critical quality attributes (CQAs) of the intermediates or ﬁnal product, which have been identiﬁed through the process. (E) The
actionable outputs of this process. To ensure product quality one should try to ensure monitoring (ideally continuously) of
the critical parameters identiﬁed using process analytical technology (PAT). This also has the advantage that the unim-
portant factors (not critical to product quality) are identiﬁed and it is possible to generate prevalidated process models and
windows of operating conditions whereby product quality is ensured. (F) List of requirements needed to perform this
process adequately.differing in their range of applicability, underlying mechanics, or where in the process they are
most useful. The crucial feature of the relationship between DoE as practiced and multivariate
methods such as the above is that by designing an experiment in a statistically optimal way
the application of any of these methods will likely beneﬁt. Brieﬂy put, the ﬁrst fundamental
principle of experimental design is to ensure there is no correlation between any pair of effects
(taken in the broadest sense to include higher-order combinations of input factors). This
essentially obviates a large part of exploratory data analysis, which largely aims to removeTrends in Biotechnology, March 2016, Vol. 34, No. 3 217
correlations and collinearities between input data points – these are highly problematic for most
machine learning and statistical methods. Simply getting all the data into a common framework
to have a large enough set to do inference on can require dropping many potentially interesting
factors and takes a lot of work. The mindset of DoE and the tools that are in development to
facilitate its adoption in this domain as well as automated logging of inputs and outputs will be a
huge step towards rectifying this situation by providing a large supply of clean data.
One key point about the difference in using this approach is that most machine learning and
multivariate methods are designed to cope as much as possible with noisy, highly correlated
legacy input data, a situation that DoE strives to avoid. Less effort has therefore been expended
on how to operate in the situation where it is possible to make more data of better quality and
more on the question of how to cope with the noisy, limited data available. The ﬁeld of active
learning and any areas relating to robotics are useful sources of insight into these problems but
they are away from the mainstream of machine learning.
In particular, the focus in DoE on trying to include as many factors as may be of interest and
engaging substantial domain knowledge in the task should remove the issue of sources of
variation that have not been measured. The expansion of sensor technology to provide information
on uncontrolled factors potentially of interest is another useful development in this regard.
The question of how to design for a machine learning approach is of great interest: there is a
practical reason for the adoption of linear models in the traditional use of DoE, which is largely
based on assumptions of the difﬁculty of experimental implementation. Given the independence
of effects up to a particular order in the design, it is likely that even though these models are not
the same as those that are being ﬁtted, they nonetheless will provide substantially cleaner data
than is usually available. As experiments become easier it is possible that the use of polynomial
basis functions may no longer be sufﬁcient for more sophisticated functions and alternative basis
sets such as splines must be chosen. In the limit of very cheap experiments, the use of uniform
designs gives optimal robustness to model misspeciﬁcation [63], although these do come at a
high experimental cost.
DoE, Systems Biology, and Screening
High-throughput screening approaches are very common and popularly used in biological
systems. In terms of the DoE approaches we have described, these typically amount to an
undirected search of a small number of factors, each with a large number of levels.
Although attractive for many reasons, including the simplicity of the experimental setup, there are
many difﬁculties with this as a method for determining biological context dependence for three
reasons:
(i) signiﬁcant biases in the underlying population being screened, leading to
(ii) a low rate of overall information processing, mandating
(iii) the necessity for high-throughput amenable assays. In most cases, these will reduce the
overall information determined per run, and in some cases imperfect proxies are used that
can mislead (e.g., the use of a ‘similar’ ﬂuorescent substrate in place of the true substrate).
There is clearly a place for screening in addressing questions that require large numbers of levels
of one or more categorical factors, particularly when a digital output is acceptable (i.e., when
trying to ﬁnd an enzyme that has activity on a substrate under ﬁxed conditions). Indeed, in some
cases screening is pragmatically necessary and can be highly effective (e.g., to screen a library
of 1010 antibody variants for binding to a cell receptor using a cell sorter). However, as a
counterpoint it is preferable to apply multivariate methods in a process of factor characterization218 Trends in Biotechnology, March 2016, Vol. 34, No. 3
to attempt to convert these large categorical factors into a smaller number of continuous
dimensions that can be more efﬁciently searched. Decreased reliance on large numbers of
experiments leads to the potential use of much better assays and a higher aggregate amount of
information processing.
Contrastingly, systems biology and DoE can be a very natural ﬁt. Although it has been argued
that prediction and explanation are often conﬂicting statistical goals [64]. There is a natural
alliance between the two: the better an explanatory, mechanistic model captures important
underlying features of the system, the better that model will predict. This essentially relates to a
question of what might be called ‘experimental phrasing’ – the choice of factors for experimental
manipulation. If the underlying components of the system and their relationships are known it is
much easier to avoid including correlated or anticorrelated factors a priori, allowing better
focused experimental questions to be asked.
A simple example of this might be found in mixture models. If we specify the components of a
solution as masses and volumes and operate with a ﬁxed total amount then certain runs end up
actually being duplicated, despite being coded differently, because the ﬁnal concentrations of the
input components are the same. This wastes experimental runs and can confuse the analysis.
Coding the system in terms of these concentrations instead leads to much greater efﬁciency.
By striving to understand what the underlying components are, in terms of the systems of life,
and how they relate to one another, the systems biology approach has a great deal to offer the
development of both predictive and explanatory models for bioprocess development.
Computational Languages for Biology
At present, the vast majority of biological knowledge is communicated in variants of natural
languages such as English. This applies whether we are describing a procedure for doing an
experiment, the results of an experiment, or our interpretation and semantic model of the
underlying system. However, natural languages are imprecise and inherently ambiguous,
leading to misinterpretation and errors in implementation. Expressing certain concepts in this
way is often very difﬁcult, leading to incompleteness. Development of appropriate languages to
express biological concepts and protocols is a highly active area of research, and one that is
crucial for enabling many of the approaches necessary for tackling highly complex systems.
Ontologies
Biological systems comprise an enormous number of parts and behaviors that must be
catalogued if they are to be meaningfully examined and manipulated. However, it is not sufﬁcient
merely to label things, for communication and interpretability by both humans and computers the
system of labels must be given a structure that deﬁnes how labels are related to one another. The
tree of life is a very well-known example of this phenomenon. The term used by computer
scientists for capturing such domain knowledge is ‘ontology’.
Many large-scale efforts at deﬁning biological ontologies have been made, including deﬁning
gene function [65], protein structures [66,67], biological sequences [68], models of biological
processes and pathways [69,70], speciﬁc biological processes in detail [71], and speciﬁc
techniques such as RT-qPCR [72]. Another important issue is the deﬁnition of equipment
and its capabilities. Many pieces of equipment are not highly complex and would not require
a sophisticated ontology, but there are clearly examples, such as mass spectrometers, which
need to be carefully described to capture their precise capabilities. Indeed such an ontology has
been created as part of a larger effort to delineate standards for proteomics analysis [73]. The
Purdue ontology is another very useful example that embeds both high-level and low-level
concepts as they relate to pharmaceutical development [74].Trends in Biotechnology, March 2016, Vol. 34, No. 3 219
Reasoning about protocols is another domain for which computational assistance is hugely
beneﬁcial. One ontology for this, the experimental factor ontology [75], has been created, but in
this case there is a better solution. Although ontologies are very useful for codifying certain types
of domain knowledge, they only represent the underlying structure indirectly. If experimental
factors can be deﬁned by embedding them into protocols in a way that ties them directly to the
implementation, then their meaning is not merely labeling but a consequence of how they are
used in that protocol. This amounts to developing a high-level programming language for
biological protocols, an ambitious goal that has already been the subject of some development.
To better understand higher level languages, ﬁrst we will introduce an intermediate concept,
domain-speciﬁc language, which is also of great importance.
Domain-Speciﬁc Languages
Domain-speciﬁc languages (DSLs) are computing languages that aim to simplify problem solving
in a restricted domain by creating a programming language dedicated to that domain. The key
point is that DSLs are designed to effectively express solutions to problems of a particular type, in
contrast to general purpose programming languages that can, less efﬁciently, express solutions
to any problem. The beneﬁt of biasing a language in this way is that programs can be expressed
in a more problem-speciﬁc manner, making programming simpler and less error-prone.
A small but growing number of DSLs for biological problem domains exist, due largely to efforts
in synthetic biology. An important example is Eugene, a DSL for specifying constructs to be
assembled in synthetic biological workﬂows [76]. This allows the underlying logic of a genetic
construct to be described for the purposes of specifying a desired construct and semantic
checking.
Another key DSL in biology is SBML; this deﬁnes an open standard for exchanging details of
metabolic simulations [70], a similar framework has also been developed as CELLML [77], which
is of particular importance in relation to physiomics. Other DSLs include examples for genetic
regulatory mechanisms [78], GENOCAD, another construct description language [79], and
Proto [80,81] – a language originally conceived for distributed spatial computing but that is
readily applicable to the cellular domain.
General Purpose Protocol Languages
DSLs are by deﬁnition restricted in scope. Each can only provide access to a small area of
biological space. A few groups have recently begun to work on high-level languages that are
intended to be general purpose descriptions of biology by combining both computational and
experimental aspects in a single description that is executable on automated hardware.
The languages that have been developed so far are extensions of general purpose programming
languages with additions to deﬁne experimental procedures. These consist primarily of liquid
handling operations, operations to change the environment such as gassing, shaking, and
temperature control, and measurement technologies such as spectrophotometry to measure
absorbance, ﬂuorescence, and emittance, or sophisticated analyses such as mass spectrome-
try. Other additions include deﬁnitions of scientiﬁc units and attempts to represent important
biological concepts, often by incorporating an existing ontology or DSL.
The ﬁrst language of this kind was the BioCoder language [82], which is built on top of the C/C++
language. The design and philosophy of this language – which aims for platform independence,
execution of arbitrary protocols, and suitably designed domain-speciﬁc abstraction of the protocol
space – are absolutely correct although the language has not to our knowledge been widely
adopted. BioCoder has however been highly inﬂuential on the design of subsequent languages,
in particular the efforts to standardize design and operation of microﬂuidics devices [83,84].220 Trends in Biotechnology, March 2016, Vol. 34, No. 3
A similar but more limited idea is seen in Transcriptic's Autoprotocol. Deﬁning an instruction set
for programming laboratory automation, Autoprotocol marries the high-level Python program-
ming language with a set of low-level commands embodied as JSON data structures detailing
pipetting operations, heating or cooling and data collection operations such as measuring
absorbance. Autoprotocol then provides a means for generating streams of such operations
using all the tools of the Python language, with tracking of samples and results happening
automatically. The purpose of this, created by cloud lab company Transcriptic, is to provide
high-level access to their services. Similar company speciﬁc interfaces exist for other automation
systems, including Tecan Script (and a C# based interface as well) by Tecan, CyBio XML for
CyBio equipment, a C based interface for Perkin Elmer equipment, and the Venus Scripting
language for Hamilton systems. In all cases, the level of abstraction is fairly low but, crucially, the
protocol is not integrated with complex data processing and logic. Once written, a protocol
remains a static sequence of commands with no possibility that the exact instruction set could
vary based on the results of measurements.
Our own language, Antha, is perhaps the ﬁrst bona ﬁde attempt to create a high-level protocol
language for general purpose computation in biology. Built atop Google's Go language [85],
Antha is an open source high-level language that combines a complete, fully featured program-
ming language with a number of domain-speciﬁc features such as liquid handling planning to
allow speciﬁcation not only of the most complex manual protocols but also to incorporate
sophisticated logic and algorithms within protocols, enabling experiments of an entirely new level
of complexity to be deﬁned. The Antha language is the central component of AnthaOS, a
service-oriented architecture providing device integration, experimental logging, stock manage-
ment, and network interfaces for external code and services.
Finally, the Klavins lab from the University of Washington recently released Aquarium, which
offers another proprietary language and execution environment, primarily for providing inventory
management and step-by-step instructions for biological workﬂows to lab technicians.
In addition to facilitating execution of complex statistical experimental designs discussed in the
ﬁrst section, the ability to express logic in a high-level language that combines design, execution,
and processing allows potential for integration of other useful algorithms to improve industrial
translation. These may include testing mechanistic models (such as multistep enzyme kinetic
models [86]), engineering parameter identiﬁcation for process design [87] and process scale-up
[88], economic [89] and environmental constraints [90], and the facilitation of metrology prin-
ciples [91] to improve reproducibility.
These languages are all relatively new and there are many open questions about what the best
language representation will be and what features are really important. Many of the advan-
tages of these approaches do not depend on these choices, however: precision and
economy of expression, integration of automation, code reuse, code generation, seamless
incorporation of informatics pipelines, and the ability to use software engineering tools to do
biology are all extremely powerful capabilities not accessible by traditional means. However,
applying these to biology is essentially a trade-off between one type of complexity and
another. New tools and metaphors are required if these sophisticated techniques are to
be made accessible.
Tools for Automation, Visualization, and Experimental Design
Managing complexity via abstraction is in itself somewhat of a complex task. Biological CAD
(computer aided design) systems are at an early stage of development with various components
of a full-featured workﬂow editor present but no uniﬁed solution. Essentially, all the tools in this
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At the lowest level, that of pure implementation, two systems for cross-platform liquid handling
with some degree of abstraction have been developed: Pr-Pr (formerly Par-Par) from JBEI, (Joint
Bioenergy Institute), which aims to provide standardized liquid handling using a high level of
abstraction and high user-friendliness with outputs to Tecan liquid handling platforms, human
execution, and a custom microﬂuidics platform [92,93]. Pr-Pr is fully open source and available
on the web.
The Clotho platform is a large-scale project aimed to produce a platform with potentially user-
developed plugins to provide a uniﬁed CAD system for synthetic biology applications [94]. This
includes aspects of construct assembly, workﬂow design, and additionally contains its own
implementation layer, Puppeteer, which is a web-based tool for designing liquid handling
implementations in the underlying cross-platform language CHRIS (Common Human-Robot
Instruction Set).
One level up from the implementation layer are tools that permit a user to design a construct for
assembly and eventual transformation into a host chassis. Several commercial offerings exist for
plasmid or construct design, but few offer signiﬁcant functionality in the case of generating large
libraries of constructs. One option that incorporates both design and implementation is the j5
system from JBEI [95,96], which is free for non-commercial use. This is integrated with other
JBEI tools including DeviceEditor [97] for visual design of large-scale devices, the ICE (inventory
of composable elements) part registry [98], and the Eugene DSL for speciﬁcation of construct
designs [76].
The Raven system [99] provides a solution for designing essentially arbitrary numbers of
constructs by a rule-based system. The user deﬁnes input parts and an assembly method
and identiﬁes constraints on the system in the form of required, forbidden, recommended, or
discouraged intermediates. The system also designs primers for PCR-based validation of the
assemblies. Raven is available free for academic use. Visualization of designed constructs is
facilitated using the pigeon platform, which provides a simple textual language for automated
production of SBOL (synthetic biology open language) visual diagrams depicting constructs
[100]. This is also freely available for academics.
Design and simulation of potential biological parts and devices is an area of overlap between
systems and synthetic biology and has therefore seen signiﬁcant software developed for a
variety of modeling situations. A selection will be covered here; for further information and
background, see [101,102].
Visual tools that blend design and simulation of biological devices include TinkerCell [103,104].
These offer ODE-based (ordinary differential equation) simulations and integration with parts
catalogs hosted locally or remotely.
At the highest level of design, with almost no user input, are tools such as AutoBioCAD, which
promise to design genetic circuits for Escherichia coli with no user interaction except the
speciﬁcation of design goals [105].
A crucial step for which many sophisticated tools exist is that of integrating the information into
knowledge, which is the domain of knowledge management systems. The increasingly compu-
tational nature of research and development we anticipate is likely to play well with these
systems. For a good recent review, see Herwig et al. [106].
The full power of these techniques is dependent on having access to automation. Traditionally
expensive and single purpose, automation has remained out of reach of many researchers222 Trends in Biotechnology, March 2016, Vol. 34, No. 3
Outstanding Questions
What is the best way to combine high-
throughput screening with model-
based experimentation?
What is the best structure for a high-level
programming language for biology?
What are the most appropriate design
goals for such a language: readability,
expressive power, or some blend of the
two?
How will we keep on top of all the
data that can now be collected and
generated?
How will security of data and auto-
mated facilities be maintained?outside of large organizations. Recent trends in low-cost, open source hardware are set to
change this trend.
Trends in Automation
Advances in automation will be key to effective implementation of these approaches. At the high
end, recent product offerings such as TAP's Ambr250 parallel bioreactor system that comprises
up to 24 parallel disposable bioreactors serviced by a liquid handling robot are starting to enable
more ambitious bioprocess development practices towards those approaches discussed in this
article. Laboratory automation has been established for decades now in pharma [107] and
bioprocessing [108], but further take-up has been slow, particularly in academia. The reason
may be partly cultural but we speculate that this is also partly due to the fact that robots tend to
be too expensive, too hard to program, and typically set-up to do one job repeatedly rather than
be ﬂexible general use tools.
There have been recent developments that are likely to transform this trend. Companies such as
Transcriptic, Emerald Cloud Lab, and Arcturus Biocloud have emerged, which allow users to
execute experiments on remote, lab infrastructure. An increasing number of vendors are
releasing professional grade lower cost liquid handlers (less than $20 000) such as the Gilson
Pipetmax and Cybio Gene-theatre. This could drop further still with the launch of open source
liquid handlers from OpenTrons and Modular Science, pricing units at less than $5000. Other
open hardware has also been produced to enable the growing DIYbio [109] community such as
thermocyclers (openPCR and openQPCR), electrophoresis tanks (Open gelbox), or combined
hardware kits (Bentobox, Amino). These are partially enabled by the use of cheap off-the-shelf
parts (such as computer fans for the thermocycler) or include 3D printing design ﬁles and
assembly instructions.
Development of cheap analytics equipment could be driven by the need for cheap diagnostics
for the developing world. Many affordable point-of-care diagnostics take advantage of the
ubiquity and technology available in mobile phones [110]. Smartphone spectrophotometers,
ﬂuorescence detectors [111–113], and microscopes [114] have already been produced. Cheap
sensors and wireless sensor networks will also play an important role. Widely available and
programmable via Rasberry Pi and Arduino, these will enable cheap bioprocess control and
monitoring of silent variables such as ambient temperature and humidity to be monitored more
effectively. Use of these sensors in open controllers has been demonstrated for related ﬁelds
such as plant cultivation [115], bee keeping [116], and wine fermentation [117].
The availability of cheap cameras presents an inadequately tapped opportunity to apply machine
vision as a means to correct errors, simplify programming (at least for the user), and enable the
use of cheaper hardware. Recently, some liquid handlers have been released that take advan-
tage of this concept (Andrews Alliance).
These trends in cheap, open, and increasingly sophisticated hardware will play a key role in
realizing the beneﬁts discussed in this article.
Concluding Remarks and Future Perspectives
High-dimensional experimentation, using one or more of the techniques discussed in this review,
is essential for harnessing biological potential, but the experiments required are often complex
and much more difﬁcult to set up than a brute-force screen. When experimenting with very large
numbers of factors, which is most likely necessary, experiments are beyond the limit of what
humans can reliably perform. Solving this problem ultimately requires automation, but the
current state of the art in laboratory automation is very much geared towards the need to
do a single process repeatedly and is not well suited to implementing designed experiments.Trends in Biotechnology, March 2016, Vol. 34, No. 3 223
New developments in software approaches to protocol speciﬁcation and implementation,
design tools, and a new generation of low-cost liquid handlers are taking place that may be
expected to provide solutions.
Of the three important technologies we have discussed, we believe the most crucial is the
development and adoption of high-level machine languages for executable bioprocesses. The
reasons for this can be simply enumerated:
(i) They provide an unambiguous medium of exchange and facilitate reuse
(ii) They remove the artiﬁcial separation between description of a process and its executable
form
(iii) Abstraction and domain language based terminology enhance readability and remove
unnecessary implementation details
(iv) Machine writing of processes is facilitated, enables automated optimization and avoids
human error
(v) Practices for managing complexity in software development become available: version
control, automated testing and validation, code validity checking, and others [118,119].
One notable feature in common with these languages is that they are all extensions of existing
programming languages: C/C++ (BioCoder), Python (Autoprotocol and Go (Antha) – this is a
necessary choice given the huge effort required to generate a full-featured programming
language and is further justiﬁed by the need for it to be readily usable without signiﬁcant effort
to encourage adoption.
However, there are many features of the physical domain that are not easily represented by
these traditional programming languages. The most appropriate way to structure a language
for this purpose is not yet apparent and has not been widely discussed ([120] is a rare exception)
and remains an interesting outstanding question that will only be answered when such lan-
guages are much more widely used.
Many initial attempts to link biological experimentation and computation have now appeared in
the literature [121–123]. One identiﬁed cause of the productivity decline in the pharmaceutical
industry, the reliance on brute-force screening, is clearly amenable to the solutions proposed
using automated optimization [12]. Other reviewers have similarly argued that more advanced
modeling will be a key part in improving the competitiveness of biotechnology [89].
At least one example in biotechnology has recently been published [124]. A number of recent
developments in Bayesian experimental design may be useful in this regard. Liepe et al. [125]
present a useful framework in which predictive accuracy is directly optimized, for instance,
building on much other recent work in the area [126–130]. An alternative approach applied to
systems biology has also recently been described [131]. Hybrid approaches that combine
mechanistic and non-mechanistic models offer a very attractive framework for addressing the
difﬁculties of combining the wealth and diversity of data that arise from conducting such complex
experiments [132–134].
Linking biotechnology more ﬁrmly with computation will bring many challenges beyond the
technical ones of making it all work correctly. Andreas et al. [135], in a stimulating article, discuss
the substantial challenges involved in keeping track of all the data merely derived from experi-
ments – particularly acute are issues relating to data security in every sense. However, the
security issues involved in making laboratory equipment and reagents accessible across the
internet are more substantial still even without the obvious technical problems.224 Trends in Biotechnology, March 2016, Vol. 34, No. 3
Adoption of these methods remains a signiﬁcant challenge (see Outstanding Questions). Will
expert molecular biologists and biotechnologists be willing to give up their pipettes and accept a
more abstracted, less hands-on view of their experiments? In some ways this is difﬁcult to
imagine; however, one of us remembers a time before kits were commonplace in molecular
biology and similar questions being asked, a fact which seems amusing in hindsight given their
present ubiquity [136]. It is to be hoped that these new technologies will be embraced as
enthusiastically and to such positive effect.
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